SEVERE CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION
Clinical trials for SEVERE CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION explained in plain language.
Never miss a new study
Get alerted when new SEVERE CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION trials appear
Sign up with your email to follow new studies for SEVERE CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered t cells with a kill switch aim to make stem cell transplants safer
Disease control OngoingThis study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…
Matched conditions: SEVERE CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New transplant method aims to cut dangerous immune reaction in half-matched donors
Disease control OngoingThis study tests a stem cell transplant method that removes certain immune cells from the donor's blood to lower the chance of graft-versus-host disease (GvHD), a serious complication. It involves 3 patients with blood cancers or non-cancerous blood disorders who lack a perfectly…
Matched conditions: SEVERE CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC